B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Raises Target Price to $73
B. Riley Adjusts Price Target on Harrow to $73 From $50, Maintains Buy Rating
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
Harrow Is Maintained at Buy by Lake Street
Harrow Analyst Ratings
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating, Announces Target Price $65
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Raises Target Price to $55
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
Craig-Hallum Gives a Buy Rating to Harrow Health (HROW)
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $50
Harrow Health's Promising Pipeline and Strategic Positioning Spur Buy Rating
Harrow Analyst Ratings
Craig-Hallum Maintains Buy on Harrow, Raises Price Target to $45
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Certara (CERT) and Harrow Health (HROW)
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $29
Harrow Health's Strong Market Performance and Growth Prospects Justify Buy Rating
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $29